Zimmer Biomet Holdings, Inc. (ZBH) EBITDA Margin: 26.94%
Is Zimmer Biomet Holdings, Inc.’s EBITDA margin high or low?
Zimmer Biomet Holdings, Inc.'s EBITDA margin of 26.94% is in line with its 5-year average of 24.72%, near the high end of its 5-year range (16.41%–30.03%).
As of Saturday, June 20, 2026. 4.21% below its 12-month average of 28.13%.
ZBH EBITDA Margin Chart
ZBH Average EBITDA Margin Chart
ZBH Current vs Average EBITDA Margin Chart
ZBH EBITDA Margin Metrics
EBITDA MARGIN
26.94%
EBITDA MARGIN AVG TTM
28.13%
EBITDA MARGIN AVG 3Y
26.95%
EBITDA MARGIN AVG 5Y
24.72%
EBITDA MARGIN AVG 10Y
23.16%
EBITDA MARGIN AVG 15Y
25.49%
EBITDA MARGIN AVG 20Y
28.23%
CURRENT VS TTM AVG
-4.21%
CURRENT VS 3Y AVG
-0.06%
CURRENT VS 5Y AVG
+8.97%
CURRENT VS 10Y AVG
+16.30%
CURRENT VS 15Y AVG
+5.68%
CURRENT VS 20Y AVG
-4.55%
ZBH Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. (ZBH) | $17.02B | 26.94% | 28.13% | 26.95% | 24.72% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 24.97% | 28.56% | 32.04% | 36.42% |
| DaVita Inc. (DVA)vs › | $13.34B | 19.37% | 20.32% | 19.37% | 19.72% |
| Medpace Holdings, Inc. (MEDP)vs › | $13.14B | 22.55% | 23.25% | 21.70% | 21.08% |
| Solventum Corporation (SOLV)vs › | $13.06B | 30.62% | 24.56% | 26.05% | 27.07% |
| Labcorp Holdings Inc. (LH)vs › | $20.98B | 14.43% | 14.18% | 13.98% | 17.86% |
| Align Technology, Inc. (ALGN)vs › | $13.04B | 18.98% | 19.70% | 20.24% | 21.46% |
| The Cooper Companies, Inc. (COO)vs › | $12.85B | 25.74% | 26.63% | 26.11% | 26.16% |
| United Therapeutics Corporation (UTHR)vs › | $22.78B | 57.15% | 57.33% | 56.99% | 52.54% |
| Revvity, Inc. (RVTY)vs › | $11.16B | 23.20% | 26.85% | 28.84% | 31.56% |
Margin Comparison
Gross Margin
70.0%
EBITDA Margin
26.9%
Operating Margin
15.6%
Net Margin
9.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
Zimmer Biomet Holdings, Inc. EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Zimmer Biomet Holdings, Inc. EBITDA Margin FAQ
- What is the EBITDA margin for Zimmer Biomet Holdings, Inc. (ZBH)?
- The EBITDA margin for ZBH stock is 26.94%.
- Is Zimmer Biomet Holdings, Inc.'s EBITDA margin high or low?
- Zimmer Biomet Holdings, Inc.'s EBITDA margin of 26.94% is in line with its 5-year average of 24.72%, near the high end of its 5-year range (16.41%–30.03%).
- What is the TTM average EBITDA margin for Zimmer Biomet Holdings, Inc. (ZBH)?
- The TTM average EBITDA margin for ZBH stock is 28.13%.
- What is the 3Y average EBITDA margin for Zimmer Biomet Holdings, Inc. (ZBH)?
- The 3Y average EBITDA margin for ZBH stock is 26.95%.
- What is the 5Y average EBITDA margin for Zimmer Biomet Holdings, Inc. (ZBH)?
- The 5Y average EBITDA margin for ZBH stock is 24.72%.
- What is the 10Y average EBITDA margin for Zimmer Biomet Holdings, Inc. (ZBH)?
- The 10Y average EBITDA margin for ZBH stock is 23.16%.
- What is the 15Y average EBITDA margin for Zimmer Biomet Holdings, Inc. (ZBH)?
- The 15Y average EBITDA margin for ZBH stock is 25.49%.
- What is the 20Y average EBITDA margin for Zimmer Biomet Holdings, Inc. (ZBH)?
- The 20Y average EBITDA margin for ZBH stock is 28.23%.
Zimmer Biomet Holdings, Inc. EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | 26.94% |
| 2024-12-31 | 29.31% |
| 2023-12-31 | 30.03% |
| 2022-12-31 | 21.54% |
| 2021-12-31 | 24.10% |
| 2020-12-31 | 16.41% |
| 2019-12-31 | 26.79% |
| 2018-12-31 | 13.35% |
| 2017-12-31 | 23.74% |
| 2016-12-31 | 23.39% |
| 2015-12-31 | 19.21% |
| 2014-12-31 | 29.49% |
| 2013-12-31 | 30.49% |
| 2012-12-31 | 31.89% |
| 2011-12-31 | 31.32% |
| 2010-12-31 | 29.87% |
| 2009-12-31 | 35.95% |
| 2008-12-31 | 34.79% |
| 2007-12-31 | 35.48% |
| 2006-12-31 | 39.16% |
| 2005-12-31 | 39.48% |
| 2004-12-31 | 34.41% |
| 2003-12-31 | 33.92% |
| 2002-12-31 | 31.06% |
| 2001-12-31 | 23.05% |
| 2000-12-31 | 27.97% |
| 1999-12-31 | 26.94% |
| 1998-12-31 | 27.53% |
Related Metrics
About Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc. (ZBH), along with its global subsidiaries, operates as a leading player in the musculoskeletal healthcare sector. The company extends its reach across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. ZBH is responsible for the design, manufacturing, and marketing of a wide array of orthopedic reconstructive solutions, including prominent knee and hip replacement systems. Their offerings also encompass Specialized Enabling Technologies (S.E.T.) products, which cover areas such as sports medicine, biologics, foot and ankle care, extremity treatments, and trauma management. Furthermore, the company provides medical devices and surgical instruments specifically for spinal conditions, alongside products for facial and cranial reconstruction. A unique part of their portfolio includes systems designed to stabilize and fixate chest bones, facilitating recovery or reconstruction following open-heart surgery, traumatic injuries, or congenital chest deformities. The company's product lines also feature a comprehensive range of dental solutions, such as reconstructive implants, prosthetics, and regenerative materials. Additionally, they are involved in robotic surgical systems, general surgical instruments, and bone cements. These advanced products and solutions are primarily utilized to address conditions in patients suffering from disorders or injuries affecting bones, joints, and their associated soft tissues. Zimmer Biomet caters to a broad clientele, including orthopedic, neuro-, and oral surgeons, dentists, hospitals, independent distributors, healthcare suppliers, and various other medical specialists. Their network further encompasses agents, healthcare purchasing organizations, and group buying alliances. Originally established in 1927, the enterprise was initially known as Zimmer Holdings, Inc., before rebranding as Zimmer Biomet Holdings, Inc. in June 2015. Its corporate headquarters are situated in Warsaw, Indiana.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ivan Tornos